Archive


Category: Arrowhead Pharmaceuticals

  • GSK aims at NASH target with $1bn-plus Arrowhead alliance

    GlaxoSmithKline has joined the ranks of drugmakers trying to develop new drugs for non-alcoholic steatohepatitis (NASH) – a condition with no approved therapies and a lengthy list of failed drug candidates – via a deal with Arrowhead Pharmaceuticals. The bolt-on deal comes – which includes an upfront payment of $120 million and up to $910 […]

  • GSK joins NASH chase, paying $120M up front for rights to Arrowhead RNAi drug

    GlaxoSmithKline sees enough promise in the early clinical data of a novel NASH drug to pay its developer, Arrowhead Pharmaceuticals, $120 million up front for rights to the experimental therapy. The Arrowhead drug uses RNA interference to “silence” an enzyme associated with the progression of the fatty liver disease.

  • Takeda strikes $1B RNAi deal with Arrowhead Pharmaceuticals

    The companies will partner on development and commercialization of ARO-AAT, Arrowhead’s Phase II RNA-interference drug for alpha-1 antitrypsin-associated liver disease, a rare genetic disorder. An analyst wrote that the deal makes sense given Takeda’s position in the AAT-augmentation therapy market.